nintedanib dry powder (SYH9061)
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 02, 2026
Nintedanib esilate powder for inhalation obtains clinical trial approval in China
(CSPC Press Release)
- "The indication for this clinical trial approval is idiopathic pulmonary fibrosis."
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1